z-logo
Premium
Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors
Author(s) -
Coban Cevayir,
Ishii Ken J.,
Gursel Mayda,
Klinman Dennis M.,
Kumar Nirbhay
Publication year - 2005
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1189/jlb.1104627
Subject(s) - immunogenicity , plasmid , biology , cpg site , dna vaccination , cpg oligodeoxynucleotide , microbiology and biotechnology , virology , antigen , oligonucleotide , dna , gene , dna methylation , immunology , genetics , gene expression
DNA vaccines, in general, have been found to be poorly immunogenic in nonhuman primates and humans as compared with mie. As the immunogenicity of DNA plasmids relies, to a large extent, on the presence of CpG motifs as built in adjuvants, we addressed the issue of poor immunogenicity by inserting recently identified CpG oligonucleotides (ODN) optimal for human (K‐type or D‐type CpG ODN) into the backbone of plasmid VR1020. We found that plasmid DNA containing K‐type CpG motifs or D‐type CpG motifs significantly enhanced the up‐regulation of surface molecules and production of interleukin‐6 from human peripheral blood mononuclear cells (PBMC) and stimulated monocytes to develop into functionally mature dendritic cells (DC) compared with unmodified plasmid. Monocyte maturation into DC was through plasmacytoid DC present in the culture. It is interesting that the K‐type CpG motif‐modified plasmid stimulated significant levels of interferon (IFN)‐γ and IFN‐α from human PBMC. Immunization of mice with D‐type CpG motif‐modified plasmid, encoding Plasmodium falciparum surface protein 25, yielded enhanced antigen‐specific antibodies. Taken together, these results suggest that insertion of immunomodulatory human CpG motifs into plasmid DNA can improve immunogenicity of DNA vaccines.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here